Anti–Phospholipase A2 Receptor 1 and Anti–Cysteine Rich Antibodies, Domain Recognition and Rituximab Efficacy in Membranous Nephropathy: A Prospective Cohort Study

医学 膜性肾病 蛋白尿 内科学 前瞻性队列研究 胃肠病学 肾病综合征 美罗华 效价 抗体 自身抗体 免疫学
作者
Piero Ruggenenti,Linda Reinhard,Barbara Ruggiero,Annalisa Perna,Luca Perico,Tobia Peracchi,Diego Fidone,Alessia Gennarini,Ariela Benigni,Monica Cortinovis,Elion Hoxha,Giuseppe Remuzzi
出处
期刊:American Journal of Kidney Diseases [Elsevier]
卷期号:83 (5): 588-600.e1 被引量:2
标识
DOI:10.1053/j.ajkd.2023.10.013
摘要

Proteinuria and anti-phospholipase A2 receptor 1 (anti-PLA2R1) antibody titers are associated with primary membranous nephropathy (MN) outcomes. We evaluated the association of antibodies against the cysteine-rich (CysR) and C-type lectin 1, 7, and 8 (CTLD1, CTLD7, and CTLD8) domains of PLA2R1 with MN outcomes.Prospective cohort study.One-hundred-thirteen consecutive, consenting patients referred to the Nephology Unit of the Azienda-Socio-Sanitaria-Territoriale (ASST) Papa Giovanni XXIII (Bergamo, Italy) with PLA2R1-related, biopsy-proven MN whose persistent nephrotic syndrome (NS) was managed conservatively for>6 months and were monitored with serial evaluations of proteinuria, autoantibodies (by enzyme-linked immunosorbent assay), and clinical outcomes.Rituximab.Complete (proteinuria<0.3g/24h) or partial (proteinuria≥0.3g/24h and<3.0g/24h with>50% reduction vs basal) NS remission.Univariable and multivariable Cox regression analyses.All patients had anti-CysR antibodies; 62 (54.9%) were multidomain recognizers. Anti-PLA2R1 and anti-CysR antibody titers were strongly correlated at baseline (P<0.001, r=0.934), 6 months (P<0.001, r=0.964), and 12 months (P<0.001, r=0.944). During a median follow-up of 37.1 (IQR, 20.3-56.9) months, 71 patients (62.8%) achieved either complete or partial remission of their NS. Lower baseline anti-PLA2R1 (HR, 0.997 [95% CI, 0.996-0.999], P=0.002) and anti-CysR [HR, 0.996 [95% CI, 0.993-0.998], P=0.001) titers were associated with a higher probability of remission, along with female sex, lower proteinuria, and lower serum creatinine levels (P<0.05 for all comparisons). Anti-CTLD antibodies were not associated with outcomes. At 6 and 12 months, compared to baseline, anti-PLA2R1 and anti-CysR antibody titers decreased more in patients progressing to partial or complete remission than in those without remission (P<0.05 for all comparisons).Observational design.In PLA2R1-related MN, anti-PLA2R1 and anti-CysR antibodies similarly predict rituximab efficacy independent of PLA2R1 domain recognition. The choice between these tests should be dictated by feasibility and costs. Evaluating anti-CTLD antibodies appears unnecessary.Primary membranous nephropathy (MN), a leading cause of nephrotic syndrome (NS) in adults, is an autoimmune disease caused by autoantibodies binding to the podocyte antigen phospholipase A2 receptor 1 (PLA2R1). We assessed whether the effects of anti-CD20 cytolytic therapy with the monoclonal antibody rituximab are associated with detection rates and levels of anti-PLA2R1 antibodies and antibodies against PLA2R1 domains such as cysteine-rich (CysR), and C-type lectin 1, 7, and 8 (CTLD1, 7, and 8), in patients with PLA2R1-related MN and persistent NS. The probability of rituximab-induced complete or partial NS remission was associated with baseline anti-PLA2R1 and anti-CysR antibody titers, but not with anti-CTLD1, 7 and 8 antibodies or multidomain recognition. Integrated evaluation of anti-PLA2R1 or anti-CysR antibodies with proteinuria and kidney function may play a role in monitoring the effects of rituximab in patients with PLA2R1-related NS and MN.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Charon发布了新的文献求助10
刚刚
兰兰爱学习完成签到,获得积分10
1秒前
2秒前
3秒前
笑点低虔完成签到 ,获得积分10
4秒前
5秒前
5秒前
6秒前
bigstone发布了新的文献求助10
8秒前
9秒前
生动的鹰发布了新的文献求助10
10秒前
达到顶峰发布了新的文献求助10
10秒前
xiongqi完成签到 ,获得积分10
11秒前
zxb发布了新的文献求助10
12秒前
14秒前
慕青应助达到顶峰采纳,获得10
14秒前
17秒前
Saber发布了新的文献求助30
17秒前
kook完成签到 ,获得积分10
19秒前
科研通AI2S应助生动的鹰采纳,获得10
21秒前
23秒前
25秒前
宿雨发布了新的文献求助10
26秒前
27秒前
尔尔完成签到,获得积分10
27秒前
28秒前
医学僧发布了新的文献求助10
31秒前
33秒前
无花果应助吾身无拘采纳,获得50
35秒前
田田完成签到,获得积分10
35秒前
宿雨完成签到,获得积分10
36秒前
今后应助科研通管家采纳,获得10
36秒前
英俊的铭应助科研通管家采纳,获得10
36秒前
隐形曼青应助科研通管家采纳,获得10
36秒前
赘婿应助科研通管家采纳,获得10
36秒前
脑洞疼应助科研通管家采纳,获得10
36秒前
桐桐应助科研通管家采纳,获得10
36秒前
天天快乐应助科研通管家采纳,获得10
37秒前
小蚂蚁应助发育不减肥采纳,获得10
37秒前
科研通AI2S应助柠檬小丸子采纳,获得10
39秒前
高分求助中
One Man Talking: Selected Essays of Shao Xunmei, 1929–1939 1000
A Chronicle of Small Beer: The Memoirs of Nan Green 1000
Understanding Autism and Autistic Functioning 950
From Rural China to the Ivy League: Reminiscences of Transformations in Modern Chinese History 900
Eric Dunning and the Sociology of Sport 850
QMS18Ed2 | process management. 2nd ed 800
Operative Techniques in Pediatric Orthopaedic Surgery 510
热门求助领域 (近24小时)
化学 医学 材料科学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 免疫学 细胞生物学 电极
热门帖子
关注 科研通微信公众号,转发送积分 2915256
求助须知:如何正确求助?哪些是违规求助? 2553517
关于积分的说明 6909030
捐赠科研通 2215300
什么是DOI,文献DOI怎么找? 1177645
版权声明 588353
科研通“疑难数据库(出版商)”最低求助积分说明 576466